TY - JOUR T1 - Insignificant effect of counter measure for coronavirus infectious disease -19 in Japan JF - medRxiv DO - 10.1101/2020.03.19.20037945 SP - 2020.03.19.20037945 AU - Yoshiyuki Sugishita AU - Junko Kurita AU - Tamie Sugawara AU - Yasushi Ohkusa Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/03/23/2020.03.19.20037945.abstract N2 - Background To control COVID-19 outbreak in Japan, sports and entertainment events were canceled in Japan for two weeks from 26 February to 13 March. It has been designated as voluntary event cancellation (VEC).Object This study predicts the effectiveness of VEC enduring and after its implementation.Method We applied a simple susceptible–infected–recovery model to data of patients with symptoms in Japan during 14 January to VEC introduction and after VEC introduction to 8 March. We adjusted the reporting delay in the latest few days.Results Results suggest that the basic reproduction number, R0, before VEC introduced as 2.29 with a 95% confidence interval (CI) was [2.19, 2.37] and the effective reproduction number, Rv, after VEC introduced as 1. 99; its 95% CI was [1.71,2.23].Discussion and Conclusion No significant effect of VEC was observed.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe author(s) received no specific funding for this work.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesJapan Ministry of Health, Labour and Welfare. Press Releases. (in Japanese) https://www.mhlw.go.jp/stf/houdou/houdou_list_202001.html. ER -